These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32678687)

  • 1. Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid.
    Vooturi S; Bourne D; Panda JJ; Choi S; Kim H; Yandrapu SK; Kompella UB
    J Ocul Pharmacol Ther; 2020; 36(6):404-409. PubMed ID: 32678687
    [No Abstract]   [Full Text] [Related]  

  • 2. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
    Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose.
    Baek IH; Kim JS; Ha ES; Choo GH; Cho W; Hwang SJ; Kim MS
    Int J Biol Macromol; 2014 Jun; 67():53-7. PubMed ID: 24631786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
    Weisfeld L; Shu Y; Shah TP
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin.
    Toropainen E; Fraser-Miller SJ; Novakovic D; Del Amo EM; Vellonen KS; Ruponen M; Viitala T; Korhonen O; Auriola S; Hellinen L; Reinisalo M; Tengvall U; Choi S; Absar M; Strachan C; Urtti A
    Pharmaceutics; 2021 Mar; 13(4):. PubMed ID: 33810564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin.
    Xie J; Luo Y; Liu Y; Ma Y; Yue P; Yang M
    Int J Nanomedicine; 2019; 14():353-369. PubMed ID: 30655668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and characterization of an orodispersible film containing drug nanoparticles.
    Shen BD; Shen CY; Yuan XD; Bai JX; Lv QY; Xu H; Dai L; Yu C; Han J; Yuan HL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1348-56. PubMed ID: 24103635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on the impact of hydroxypropyl methylcellulose on the viscosity of PEG melt suspensions using surface plots and principal component analysis.
    Oh CM; Heng PW; Chan LW
    AAPS PharmSciTech; 2015 Apr; 16(2):466-77. PubMed ID: 25370022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of budesonide-loaded polycaprolactone nanobeads by electrospraying for controlled drug release.
    Midhun BT; Shalumon KT; Manzoor K; Jayakumar R; Nair SV; Deepthy M
    J Biomater Sci Polym Ed; 2011; 22(18):2431-44. PubMed ID: 21144167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular Drug Delivery System-based on Solid Nanoparticles].
    Nagai N
    Yakugaku Zasshi; 2021; 141(1):47-53. PubMed ID: 33390447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of a poorly water-soluble compound to hair follicles using polymeric nanoparticle suspensions.
    Morgen M; Lu GW; Du D; Stehle R; Lembke F; Cervantes J; Ciotti S; Haskell R; Smithey D; Haley K; Fan C
    Int J Pharm; 2011 Sep; 416(1):314-22. PubMed ID: 21722722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
    Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
    Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
    Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
    Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops.
    Loftsson T; Hreinsdóttir D; Stefánsson E
    J Pharm Pharmacol; 2007 May; 59(5):629-35. PubMed ID: 17524227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.
    Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L
    AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
    Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
    Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant.
    Ha ES; Choo GH; Baek IH; Kim JS; Cho W; Jung YS; Jin SE; Hwang SJ; Kim MS
    Int J Biol Macromol; 2015 Jan; 72():218-22. PubMed ID: 25159878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
    Date AA; Halpert G; Babu T; Ortiz J; Kanvinde P; Dimitrion P; Narayan J; Zierden H; Betageri K; Musmanno O; Wiegand H; Huang X; Gumber S; Hanes J; Ensign LM
    Biomaterials; 2018 Dec; 185():97-105. PubMed ID: 30236840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies.
    Zhang Y; Zhang J
    Artif Cells Nanomed Biotechnol; 2016; 44(1):285-9. PubMed ID: 25100657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.